[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"retinal-vascular-disorder\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:retinal-vascular-disorder":31},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,45,73],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100401313","optical-coherence-tomography-angiography-in-subjects-with-retinal-vascular-disease-100401313",false,"NCT04505618","Optical Coherence Tomography Angiography in Subjects With Retinal Vascular Disease","OCTA-RVD","Exclusion Criteria:\n\n* Both subjects with diseases and controls:\n* Children (age\\\u003C18)\n* Pregnant females\n* Developmentally delayed subjects\n* Subjects unable to provide informed consent\n* Inability to cooperate with tests and study instructions\n* Images with motion artifact or signal strength \\\u003C 7\n* History of glaucoma\n* History of age-related macular degeneration\n* History of any visually significant eye disease\n* History of proliferative diabetic retinopathy\n* History of any inflammatory disease\n* History of heart disease\n* History of thyroid disease.\n* Additional criteria for controls:\n* History of any type of Diabetes Mellitus\n* History of any type of Hypertension",true,"ALL","18 Years","99 Years",{"count":21,"type":22},1050,"ESTIMATED","INTERVENTIONAL",[25],"NA","This study will perform a prospective, longitudinal analysis of clinical and imaging findings from normal controls and subjects with retinal vascular disease to better define the diagnostic imaging criteria that signify change in disease stage. This includes disease progression in early stages of disease or disease regression with appropriate standard-of-care treatment.",[28,29,30,31],"Diabetic Retinopathy","Retinal Vein Occlusion","Hypertension,Essential","Retinal Vascular Disorder","RECRUITING","2026-06-15",{"date":35,"type":36},"2026-06-17","ACTUAL",{"date":38,"type":36},"2019-10-01",{"date":40,"type":22},"2027-09-01",{"name":42,"class":43},"Johns Hopkins University","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":52,"enrollmentInfo":53,"targetDuration":4,"studyType":23,"phases":55,"briefSummary":56,"conditions":57,"keywords":59,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":4},"100592174","study-of-human-ocular-hemodynamics-by-holography-dopple-100592174","NCT06989996","Study of Human Ocular Hemodynamics by Holography Dopple","HoLoEye","Inclusion Criteria:\n\nCriteria common to both populations ( patients and healthy volunteers) :\n\n* Age ≥ 18 years and \\\u003C 75 years;\n* Having received informed information about the study and having signed a consent to participate in the study;\n* Affiliated or covered by social security\n\nCriteria for healthy volunteers :\n\nNo ocular or systemic disease deemed to affect ocular circulation by an investigator\n\nSpecific criteria for patients:\n\n* Subjects usually followed at one of the recruiting centers;\n* Patients with chronic glaucoma, for whom a therapeutic modification is planned in the short term;\n* Patients with carotid stenosis;\n* Patients with choroidal pathology: pachychoroidism having led to pigment epithelium anomalies.\n\nExclusion Criteria:\n\n* For all participants:\n* Persons covered by articles L1121-5 to L1121-8 of the CSP (all protected persons: pregnant women, parturients, nursing mothers, persons deprived of their liberty by judicial decision or administrative decision, minors, and persons under legal protection: guardianship or curatorship);\n* Women of childbearing age not using an effective method of contraception, or positive pregnancy test (blood or urine);\n* Participants allergic to tropicamide when using pupillary dilatation;\n* Inability of the subject to maintain a stable sitting position for research procedures;\n* Temporary contraindication to HoloDoppler:\n\n  * Patient suffering from viral conjunctivitis or any other infectious disease;\n  * Patient with skin lesions on the neck or forehead, for which contact with a chin strap is not recommended.\n* Impossibility of making acquisitions of interest (e.g. due to a pupil diameter that is too small, advanced cataracts, nystagmus, etc.).\n* Wearing glasses or contact lenses to correct a refractive disorder is not considered a criterion for non-inclusion.","74 Years",{"count":54,"type":22},148,[25],"Prospective, interventional, non-randomized, open-label study, multi-center, Gehan-designed study with sequential inclusions in each subgroup, ranging from 4 subjects to a maximum 37 subjects per subgroup included",[58,31],"Glaucoma",[60,61,62],"glaucoma","pachychoroid,","carotid stenosis","NOT_YET_RECRUITING","2025-05-16",{"date":66,"type":36},"2025-05-25",{"date":68,"type":22},"2025-06",{"date":70,"type":22},"2028-06",{"name":72,"class":43},"Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts",{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":77,"acronym":4,"eligibilityCriteria":78,"healthyVolunteers":11,"sex":17,"minAge":79,"maxAge":18,"enrollmentInfo":80,"targetDuration":4,"studyType":23,"phases":82,"briefSummary":84,"conditions":85,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":44},"100556078","phase-4-safety-and-efficacy-of-18-mm-short-vitrectomy-probe-for-pediatric-vitreoretinal-surgeries-100556078","NCT06520410","Safety and Efficacy of 18 mm Short Vitrectomy Probe for Pediatric Vitreoretinal Surgeries","Inclusion Criteria:\n\n* Patients less than 18 years old\n* Need vitrectomy due to various etiologies, including retinopathy of prematurity, familial exudative vitreoretinopathy, persistent fetal vasculature, congenital cataract, lens dislocation, open-globe injury, vitreous hemorrhage, or other vitreoretinal diseases.\n\nExclusion Criteria:\n\n* Patients who cannot cooperate fully with detailed ophthalmic examinations.","0 Years",{"count":81,"type":22},60,[83],"PHASE4","This study aims to study the safety and efficacy of using an 18 mm short vitrectomy probe for pediatric vitreoretinal surgeries and to investigate the surgeon's comfort and reliability of using the shorter probe.",[86,87,88,89,90,91,92,93,31],"Retinopathy of Prematurity Both Eyes","Retinal Disease","Persistent Fetal Vasculature","Coats Disease","Coats Retinopathy","Familial Exudative Vitreoretinopathies","Vitreous Disorder","Vitreous Anomalies","2024-07-21",{"date":96,"type":36},"2024-07-25",{"date":98,"type":36},"2024-03-05",{"date":100,"type":22},"2028-02-28",{"name":102,"class":43},"Chang Gung Memorial Hospital"]